COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,387 Articles (22,816 medRxiv, 8,571 bioRxiv)

Most recent first Previous |  Page 881: Articles 8801-8810  | Next

Hospital length of stay in a mixed Omicron and Delta epidemic in New South Wales, Australia
Tobin, R. J., Wood, J. G., Jayasundara, D., Sara, G., Walker, J., Martin, G., McCaw, J. M., Shearer, F. M., Price, D. J.
10.1101/2022.03.16.22271361 — Posted: 2022-03-19
COVID-19 patients have increased levels of membrane-associated and soluble CD48
Pahima, H., Zaffran, I., Ben-Chetrit, E., Jarjoui, A., Gaur, P., Manca, M. L., Reichmann, D., Orenbuch-Harroch, E., Puxeddu, I., Zinner, C., Tzankov, A., Levi-Schaffer, F.
10.1101/2022.03.18.484843 — Posted: 2022-03-19
Modelling the impact of non-pharmaceutical interventions on workplace transmission of SARS-CoV-2 in the home-delivery sector
Whitfield, C. A., Van Tongeren, M., Han, Y., Wei, H., Daniels, S. A., Regan, M., Denning, D. W., Verma, A., Pellis, L., University of Manchester COVID-19 Modelling Group, , Hall, I.
10.1101/2022.03.17.22272414 — Posted: 2022-03-18
Monoclonal antibody and antiviral therapy for treatment of mild-to-moderate COVID-19 in pediatric patients
Vora, S. B., Englund, J. A., Trehan, I., Waghmare, A., Kong, A., Adler, A., Zerr, D. M.
10.1101/2022.03.16.22272511 — Posted: 2022-03-18
Mobility was a Significant Determinant of Reported COVID-19 Incidence During the Omicron Surge in the Most Populous U.S. Counties
Harris, J. E.
10.1101/2022.03.16.22272523 — Posted: 2022-03-18
Protection of prior natural infection compared to mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar
Chemaitelly, H., Ayoub, H., AlMukdad, S., Coyle, P., Tang, P., YASSINE, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G., Al Kuwari, M. G., Butt, A. A., Al Romaihi, H. E., Al-Thani, M. H., Al-Khal, A., Bertollini, R., Abu-Raddad, L. J.
10.1101/2022.03.17.22272529 — Posted: 2022-03-18
A log-odds system for waning and boosting of COVID-19 vaccine effectiveness
Blakely, T., Szanyi, J., Wilson, T., Scott, N.
10.1101/2022.03.16.22272519 — Posted: 2022-03-18
Founder effect contributes to the unique pattern of SARS-CoV-2 variant B.1.1.519 emergence in Alaska
Haan, T. J., Smith, L. K., DeRonde, S., House, E., Zidek, J., Puhak, D., Redlinger, M., Parker, J., Barnes, B. M., Burkhead, J. L., Knall, C., Bortz, E., Chen, J., Drown, D. M.
10.1101/2022.03.17.22272446 — Posted: 2022-03-18
Suppression of de novo antibody responses against SARS-CoV2 and the Omicron variant after mRNA vaccination and booster in patients with B cell malignancies undergoing active treatment, but maintenance of pre-existing antibody levels against endemic viruses.
Azar, J., Evans, J. P., Sikorski, M., Chakravarthy, K., McKenney, S., Carmody, I., Zeng, C., Teodorescu, R., Song, N. J., Hamon, J., Bucci, D., Velegraki, M., Bolyard, C., Weller, K. P., Reisinger, S., Bhat, S. A., Maddocks, K. J., Gumina, R. J., Vlasova, A. N., Oltz, E. M., Saif, L. J., Chung, D., Woyach, J. A., Shields, P. G., Liu, S.-L., Li, Z., Rubinstein, M. P.
10.1101/2022.03.17.22272389 — Posted: 2022-03-18
Selection of appropriate reference genes for normalization of qRT-PCR based gene expression analysis in SARS-CoV-2, and Covid-associated Mucormycosis infection
Kumar, S., Ahmad, A., Kushwaha, N., Negi, S., Gautam, K., Singh, A., Tiwari, P., Garg, R., Agarwal, R., Mohan, A., Trikha, A., Thakar, A., Saini, V.
10.1101/2022.03.15.22272441 — Posted: 2022-03-18

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).